RU2004129573A - Жевательная таблетка с приятным вкусом - Google Patents

Жевательная таблетка с приятным вкусом Download PDF

Info

Publication number
RU2004129573A
RU2004129573A RU2004129573/15A RU2004129573A RU2004129573A RU 2004129573 A RU2004129573 A RU 2004129573A RU 2004129573/15 A RU2004129573/15 A RU 2004129573/15A RU 2004129573 A RU2004129573 A RU 2004129573A RU 2004129573 A RU2004129573 A RU 2004129573A
Authority
RU
Russia
Prior art keywords
tablet
additional excipients
cyclodextrin
combination
cetirizine
Prior art date
Application number
RU2004129573/15A
Other languages
English (en)
Inventor
Касра КАСРАЯН (US)
Касра КАСРАЯН
Тан ХАВЛИР (US)
Таня ХАВЛИР
Original Assignee
Пфайзер Продактс Инк. (Us)
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. (Us), Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк. (Us)
Publication of RU2004129573A publication Critical patent/RU2004129573A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (12)

1. Жевательная таблетка с приятным вкусом, включающая:
(а) цетиризин или его фармацевтически приемлемую соль,
(b) подсластитель,
(с) комбинацию виноградного ароматизатора и ванильного ароматизатора в сочетании от примерно 4:1 до 2:1,
(d) циклодекстрин,
(е) один или более дополнительных эксципиентов.
2. Таблетка по п. 1, где указанная фармацевтически приемлемая соль цетиризина представляет собой дигидрохлорид цетиризина.
3. Таблетка по п. 1, дополнительно включающая красный, голубой или пурпурный красители.
4. Таблетка по п. 1, где указанный циклодекстрин представляет собой бета-циклодекстрин.
5. Таблетка по п. 2, где указанный циклодекстрин представляет собой бета-циклодекстрин.
6. Таблетка по п. 1, указанный один или несколько дополнительных эксципиентов выбирают из группы, состоящей из стеарата магния, коллоидного диоксида кремния, безводной лактозы, микрокристаллической целлюлозы, модифицированной гуаровой камедью микрокристаллической целлюлозы, кроскармелозы натрия, маннита, сахарозы и декстринизированной сахарозы.
7. Таблетка по пп. 1, 2, 3, 4, 5 или 6, где указанный подсластитель представляет собой ацесульфам калия.
8. Жевательная двухслойная таблетка с приятным вкусом, включающая:
(а) первый слой, состоящий из:
(i) цетиризина или его фармацевтически приемлемой соли,
(ii) комбинации виноградного ароматизатора и ванильного ароматизатора в сочетании от примерно 4:1 до 2:1,
(iii) бета-циклодекстрина,
(iv) красители;
(v) одного или более дополнительных эксципиентов; и
(b) второй слой, состоящий из:
(i) маннита или декстринизированной сахарозы,
(ii) комбинации виноградного ароматизатора и ванильного ароматизатора в сочетании от примерно 4:1 до 2:1,
(iii) красителей и
(iv) одного или более дополнительных эксципиентов.
9. Таблетка по п. 8, где указанная фармацевтически приемлемая соль цетиризина представляет собой дигидрохлорид цетиризина.
10. Таблетка по п. 8 или 9, где указанный один или несколько дополнительных эксципиентов в указанном первом слое выбирают из группы, состоящей из стеарата магния, коллоидного диоксида кремния, безводной лактозы, микрокристаллической целлюлозы, модифицированной гуаровой камедью микрокристаллической целлюлозы, и кроскармелозы натрия.
11. Таблетка по п. 8 или 9, где указанный один или несколько дополнительных эксципиентов в указанном втором слое представляет собой стеарат магния.
12. Таблетка по п. 10, где указанный один или несколько дополнительных эксципиентов в указанном втором слое представляет собой стеарат магния.
RU2004129573/15A 2002-04-04 2003-03-26 Жевательная таблетка с приятным вкусом RU2004129573A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37008602P 2002-04-04 2002-04-04
US60/370,086 2002-04-04

Publications (1)

Publication Number Publication Date
RU2004129573A true RU2004129573A (ru) 2005-04-10

Family

ID=28792024

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004129573/15A RU2004129573A (ru) 2002-04-04 2003-03-26 Жевательная таблетка с приятным вкусом

Country Status (23)

Country Link
US (1) US7482022B2 (ru)
EP (1) EP1494654B1 (ru)
JP (1) JP2005526104A (ru)
KR (1) KR20040098036A (ru)
CN (1) CN100335041C (ru)
AR (1) AR039242A1 (ru)
AT (1) ATE388693T1 (ru)
BR (1) BR0308927A (ru)
CA (1) CA2481025A1 (ru)
DE (1) DE60319685T2 (ru)
ES (1) ES2298540T3 (ru)
HN (1) HN2003000112A (ru)
IL (1) IL164106A0 (ru)
MX (1) MXPA04009617A (ru)
NO (1) NO20044774L (ru)
PA (1) PA8570601A1 (ru)
PE (1) PE20030950A1 (ru)
PL (1) PL372904A1 (ru)
RU (1) RU2004129573A (ru)
TW (1) TW200401651A (ru)
UY (1) UY27746A1 (ru)
WO (1) WO2003084511A1 (ru)
ZA (1) ZA200407537B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004123612A (ru) * 2002-01-15 2005-04-20 ЮСиБи ФАРШИМ С.А. (CH) Фармацевтическая композиция для перорального применения
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
JP2008507504A (ja) * 2004-07-22 2008-03-13 ファイザー・プロダクツ・インク 溶解遅延形態の薬物及び/又は溶解増進形態のシクロデキストリンを含む味マスキング製剤
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PT2522365T (pt) 2004-11-24 2017-02-08 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
WO2009006898A1 (en) * 2007-07-11 2009-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
WO2009006899A1 (en) * 2007-07-11 2009-01-15 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
WO2009006892A1 (en) * 2007-07-11 2009-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising antioxidant
CL2008003230A1 (es) * 2007-11-01 2009-11-27 Sanofi Aventis Healthcare Pty Ltd Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta.
RU2583920C2 (ru) 2009-11-13 2016-05-10 Астразенека Аб Композиция двухслойной таблетки
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2013129436A1 (ja) * 2012-02-29 2013-09-06 武田薬品工業株式会社 経口剤
DK2861236T3 (da) 2012-06-15 2019-10-14 Pharmathen Sa Farmaceutisk sammensætning, der indeholder phosphatbindende polymer
CN102716099B (zh) * 2012-07-05 2013-10-09 湖南千金湘江药业股份有限公司 盐酸左西替利嗪咀嚼片及其制备方法
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
JP2016094364A (ja) * 2014-11-14 2016-05-26 ニプロ株式会社 安定化および苦味抑制された口腔内崩壊製剤
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
JP2019001730A (ja) * 2017-06-13 2019-01-10 武田テバファーマ株式会社 安定な経口医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558600A (en) 1967-07-28 1971-01-26 Abbott Lab Alkyl sulfate salts of 1-(p-chlorobenzhydryl)-4-methylhomopiperazines
NO155805C (no) 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US4650663A (en) 1983-07-20 1987-03-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IL91398A (en) 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
EP0542926B1 (en) 1990-08-07 1995-02-15 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
NZ256346A (en) 1992-10-09 1997-04-24 Procter & Gamble Medicaments containing 3-l-menthoxypropane-1,2-diol for treating cold symptoms
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
RU2004123612A (ru) * 2002-01-15 2005-04-20 ЮСиБи ФАРШИМ С.А. (CH) Фармацевтическая композиция для перорального применения

Also Published As

Publication number Publication date
KR20040098036A (ko) 2004-11-18
ZA200407537B (en) 2006-06-28
AR039242A1 (es) 2005-02-16
PE20030950A1 (es) 2003-11-12
US20030215503A1 (en) 2003-11-20
MXPA04009617A (es) 2005-01-11
UY27746A1 (es) 2003-10-31
HN2003000112A (es) 2004-05-05
DE60319685D1 (de) 2008-04-24
DE60319685T2 (de) 2009-03-26
ES2298540T3 (es) 2008-05-16
AU2003209953A1 (en) 2003-10-20
JP2005526104A (ja) 2005-09-02
CN1642531A (zh) 2005-07-20
WO2003084511A1 (en) 2003-10-16
IL164106A0 (en) 2005-12-18
CN100335041C (zh) 2007-09-05
NO20044774L (no) 2004-11-03
CA2481025A1 (en) 2003-10-16
US7482022B2 (en) 2009-01-27
BR0308927A (pt) 2005-01-04
EP1494654A1 (en) 2005-01-12
PL372904A1 (en) 2005-08-08
EP1494654B1 (en) 2008-03-12
ATE388693T1 (de) 2008-03-15
TW200401651A (en) 2004-02-01
PA8570601A1 (es) 2003-12-10

Similar Documents

Publication Publication Date Title
RU2004129573A (ru) Жевательная таблетка с приятным вкусом
JP2005526104A5 (ru)
Roberts et al. Right-sided valvular infective endocarditis: a clinicopathologic study of twelve necropsy patients
Greenspan Treatment of oral candidiasis in HIV infection
Martínez-Pallí et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome
NZ598993A (en) Multi-portion intra-oral dosage form with organoleptic properties
Seraj et al. Oro-dental health status and salivary characteristics in children with chronic renal failure
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
Hookey et al. Combined low-volume polyethylene glycol solution plus stimulant laxatives versus standard-volume polyethylene glycol solution: a prospective, randomized study of colon cleansing before colonoscopy
CA2563748A1 (en) Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
CA2608220A1 (en) Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus
KR100588224B1 (ko) 페린도프릴을 포함하는 경구분산가능한 약제학적 조성물
JP4190769B2 (ja) 内服液組成物
HUP0201307A2 (hu) Ízfedett gyógyszerkészítmények
US20100040557A1 (en) Double-layered zaleplon- contained tablet
USD572051S1 (en) Loft bed headboard/footboard
JP2009196940A (ja) 口腔内速崩壊錠及びその製造法
Tinker et al. Severe pulmonary hypertension in Ullrich-Noonan syndrome.
USD478748S1 (en) Swing chair support frame
Leboulanger L’obstruction nasale de l’enfant
Casu et al. Hairy tongue, geographic tongue, scrotal tongue and systemic connections: Clinical images and an overview
Hang et al. Patent ductus arteriosus presenting in old age
USD980411S1 (en) Face mask
USD459099S1 (en) Swing chair support frame
USD482890S1 (en) Seat

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060310